Welcome to our dedicated page for Insmed news (Ticker: INSM), a resource for investors and traders seeking the latest updates and insights on Insmed stock.
News and press releases about Insmed Incorporated (INSM) provide insight into the company’s progress as a global biopharmaceutical organization focused on serious and rare diseases. Insmed regularly issues updates on its commercial performance, clinical trial milestones, regulatory decisions, and corporate initiatives across its respiratory, immunology & inflammation, and neuro & other rare disease programs.
Recent news has highlighted key events such as U.S. Food and Drug Administration approval of BRINSUPRI (brensocatib) for non-cystic fibrosis bronchiectasis, European Commission approval of BRINSUPRI for specified NCFB patients in the European Union, and detailed business updates around the commercial launch of BRINSUPRI and continued global growth of ARIKAYCE (amikacin liposome inhalation suspension). Investors can also follow announcements on the advancement of TPIP (treprostinil palmitil inhalation powder) into Phase 3 studies for pulmonary hypertension associated with interstitial lung disease and other pulmonary indications.
Insmed’s news flow also covers clinical data readouts from studies such as ASPEN and WILLOW in NCFB, the BiRCh and CEDAR trials evaluating brensocatib in additional neutrophil-mediated diseases, and early-stage developments in gene therapy programs INS1201, INS1202, and INS1203. Corporate communications include financial results, conference presentations at major healthcare and respiratory congresses, and updates on acquisitions such as INS1148, an investigational monoclonal antibody for respiratory and inflammatory conditions.
For followers of INSM stock, this news page offers a centralized view of Insmed’s ongoing commercial execution, regulatory interactions, and pipeline evolution. Regular updates help track how the company’s therapies and investigational candidates are progressing through development and reaching patient populations worldwide.
Insmed (Nasdaq: INSM) announced inducement grants for 97 new employees on August 2, 2024. The grants, approved under NASDAQ Listing Rule 5635(c)(4), include options to purchase a total of 133,130 shares at $75.33 per share, the closing price on the grant date, August 1, 2024.
The options have a 10-year term and follow a four-year vesting schedule: 25% vests after the first year, and 12.5% every six months thereafter, contingent on continued employment.
Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company focused on rare diseases, has announced its upcoming second-quarter 2024 financial results conference call. The call is scheduled for Thursday, August 8, 2024, at 8:00 a.m. ET. Investors and interested parties can participate by dialing (888) 210-2654 (U.S.) or (646) 960-0278 (international) with access code 7862189. The call will also be webcast live on the company's website.
A replay of the conference call will be available until September 7, 2024, and a webcast recording will be archived for 90 days on Insmed's website. This event provides an opportunity for stakeholders to gain insights into Insmed's financial performance and receive updates on the company's business activities.
Insmed, a global biopharmaceutical company, announced inducement grants to 18 new employees under NASDAQ Listing Rule 5635(c)(4). The grants, approved by Insmed's Compensation Committee, include options to purchase 38,110 shares of Insmed common stock at an exercise price of $66.34 per share. These options, granted on July 1, 2024, have a 10-year term and a four-year vesting schedule. Specifically, 25% of the shares will vest on the first anniversary of the grant date, with 12.5% vesting every six months thereafter, conditional upon the employees' continued service. This move aligns with Insmed's mission to transform the lives of patients with serious and rare diseases by attracting and retaining top talent.
Insmed announced additional positive results from the ASPEN study on brensocatib at the 7th World Bronchiectasis Conference. The study assessed efficacy, safety, and tolerability of brensocatib in non-cystic fibrosis bronchiectasis. Key findings include a 21.1% risk reduction in pulmonary exacerbations for the 10 mg group and 19.4% for the 25 mg group, compared to placebo. The 25 mg dose also showed significantly less decline in lung function (FEV1) and forced vital capacity (FVC). Both doses improved Quality of Life scores, with nominally significant improvements in the 25 mg group. Brensocatib demonstrated a favorable safety profile, with common adverse events including COVID-19 and nasopharyngitis. Insmed plans to file a New Drug Application with the FDA in Q4 2024, with a potential U.S. launch in mid-2025, followed by Europe and Japan in 2026.
Insmed announced the redemption of all $225 million in outstanding 1.75% Convertible Senior Notes due 2025. The redemption date is set for August 9, 2024, and the redemption price will be 100% of the principal amount plus accrued interest, totaling approximately $1,001.17 per $1,000 principal. Interest on the Notes will cease to accrue after this date. Holders may convert their Notes into shares of Insmed common stock at a rate of 25.5384 shares per $1,000 principal until August 8, 2024. This conversion could result in up to 5,746,140 shares being issued if all Notes are converted.
Insmed, a global biopharmaceutical company, announced the granting of inducement awards to 15 new employees under NASDAQ Listing Rule 5635(c)(4). Approved by Insmed's Compensation Committee, the awards serve as a material inducement for their employment. On June 3, 2024, the employees received options to purchase 49,340 shares of Insmed common stock at $55.94 per share, the closing price on the grant date. The options have a 10-year term and a four-year vesting schedule, with 25% vesting after one year and 12.5% every six months thereafter, contingent on continued employment.
Insmed, a global biopharmaceutical company, will present at the Goldman Sachs 45th Annual Global Healthcare Conference on June 10, 2024, in Miami. Management will engage in a fireside chat at 10:00 a.m. ET, which will be webcast live. The webcast will be accessible via Insmed's investor relations website and will remain archived for 30 days post-event.
Insmed will host a commercial webinar on June 4, 2024, at 8:00 a.m. ET to discuss the market outlook for its key programs: ARIKAYCE®, brensocatib, and TPIP. Shareholders and interested parties can join the conference call by dialing (800) 715-9871 (U.S.) or (646) 307-1963 (international) with access code 7504027. The call will also be webcast on Insmed's website and a replay will be available until July 4, 2024. The archived webcast will be accessible for 90 days in the Investor Relations section on the company’s site.
Insmed announced the pricing of a public offering of 12,621,359 shares of common stock at $51.50 per share, targeting $650 million in gross proceeds. An additional 1,893,203 shares are available to underwriters within a 30-day option. The funds will support research and development, commercialization of brensocatib, and other corporate purposes. Closing is expected on May 31, 2024, subject to customary conditions. Goldman Sachs, Leerink Partners, and J.P. Morgan lead the offering.
Insmed (Nasdaq: INSM), a biopharmaceutical company, has announced a proposed public offering of $500 million worth of its common stock. The company intends to provide underwriters with a 30-day option to purchase up to an additional 15% of the shares. All shares will be sold by Insmed, with Goldman Sachs & Co. and Leerink Partners acting as joint book-running managers. The offering is dependent on market conditions and other factors, and there is no assurance of its completion or terms. The public offering will be made through Insmed's shelf registration statement filed with the SEC, which became effective on May 19, 2023. Preliminary prospectus supplements will be available on the SEC's website in due course.